Floatz logo

Devimistat

Duct Cell Adenocarcinoma of the Pancreas

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversitySmall moleculePhase 2Dormant
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
36/ 100
Competitive Position
89/ 100

Competitive context

283 Active assets in the Duct Cell Adenocarcinoma of the Pancreas cohort.

Asset / SponsorPhaseRating
Irinotecan
NRG Oncology
Phase 3BB
Daraxonrasib
Revolution Medicines, Inc.
Phase 3BB
IMMUNOGLOBULIN G2, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 HEAVY CHAIN) DISULPHIDE WITH HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 LIGHT CHAIN, DIMER
OHSU Knight Cancer Institute
Phase 2BB
Rmc-6236
Tango Therapeutics, Inc.
Phase 3BB
S-1
Genentech, Inc.
Phase 2BB

View all 50 →

Same molecule, other indications

Devimistat is also rated in:

acute myeloid leukemiaDormant
CCC
Indicative ·
54 / 100
View asset →
malignant pancreatic neoplasmDormant
CCC
Indicative ·
51 / 100
View asset →
acute myeloid leukemiaDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →